Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 19/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24298081 | 0.88 | SCN10A (0.67) | SCN10ANR1I2CACNA1C | |
| SCHEMBL23779509 | 0.85 | CA1 (0.51) | SCN10A | |
| SCHEMBL23779441 | 0.84 | SCN10A (0.77) | SCN10ANR1I2CACNA1C | |
| SCHEMBL23779478 | 0.84 | SCN10A (0.70) | SCN10ANR1I2CACNA1C | |
| SCHEMBL23779468 | 0.81 | SCN10A (0.70) | SCN10ANR1I2CACNA1C | |
| SCHEMBL23779443 | 0.81 | SCN10A (0.79) | SCN10ANR1I2CACNA1C | |
| SCHEMBL23779504 | 0.81 | SCN10A (0.78) | SCN10ANR1I2CACNA1C | |
| SCHEMBL23779559 | 0.80 | SCN10A (1.00) | SCN10ANR1I2CACNA1C | |
| SCHEMBL29615281 | 0.80 | SCN10A (1.00) | SCN10ANR1I2CACNA1C | |
| SCHEMBL23779565 | 0.79 | SCN10A (1.00) | SCN10ANR1I2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | claimed |
| EP-3873468-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | claimed |
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3873468-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119363-A1 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | SCN10A 8/4885NR1I2 1210/4885CACNA1C 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.